MicroAlgo Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MicroAlgo Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $87.13M | Mar 29, 2023 |
| FY2022 | Dec 31, 2021 | $82.04M | Mar 29, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $18.95M | Mar 29, 2023 |
| FY2022 | Dec 31, 2021 | $33.12M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($117.8K) | Mar 25, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($6.96M) | Mar 29, 2023 |
| FY2022 | Dec 31, 2021 | $8.57M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($117.8K) | Mar 25, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($7.86M) | Mar 29, 2023 |
| FY2022 | Dec 31, 2021 | $8.05M | Mar 29, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $13.93M | Mar 29, 2023 |
| FY2022 | Dec 31, 2021 | $16.59M | Mar 29, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $5.13M | Mar 29, 2023 |
| FY2022 | Dec 31, 2021 | $5.28M | Mar 29, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $1.96M | Mar 29, 2023 |
| FY2022 | Dec 31, 2021 | $15.27M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($77.8K) | Mar 25, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $160.9K | Mar 29, 2023 |
| FY2022 | Dec 31, 2021 | $36.0K | Mar 29, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $72.09M | Mar 29, 2023 |
| FY2022 | Dec 31, 2021 | $81.61M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $191.5K | Mar 25, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $5.08M | Mar 29, 2023 |
| FY2022 | Dec 31, 2021 | $22.97M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $295.2K | Mar 25, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $66.76M | Mar 29, 2023 |
| FY2022 | Dec 31, 2021 | $58.40M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($103.7K) | Mar 25, 2022 |
| FY2021 | Dec 31, 2019 | $14.1K | Mar 25, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $15.26M | Mar 29, 2023 |
| FY2022 | Dec 31, 2021 | $21.95M | Mar 29, 2023 |
| FY2022 | Dec 31, 2020 | $22.53M | Mar 29, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $19.14M | Mar 29, 2023 |
| FY2022 | Dec 31, 2021 | $26.48M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($128.7K) | Mar 25, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $42.75M | Mar 29, 2023 |
| FY2022 | Dec 31, 2021 | $42.72M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $239 | Mar 25, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 43.86M | Mar 29, 2023 |
| FY2022 | Dec 31, 2021 | 39.60M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 1.15M | Mar 25, 2022 |